好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Long-term socioeconomic outcomes associated with pediatric-onset multiple sclerosis: A nationwide prospective cohort study
Multiple Sclerosis
MS and CNS Inflammatory Disease Posters (7:00 AM-5:00 PM)
172
To evaluate the association between pediatric-onset MS (PoMS) and education and income throughout adulthood.   
PoMS can lead to significant cognitive and physical disability. Whether this translates into quantifiable differences in educational achievements and earnings throughout the lifespan is unknown.

Prospective cohort study of PoMS and population-based references, using Swedish nationwide microdata from 1990-2016. PoMS (onset < 18 years) were identified in the Swedish MS Registry. The non-MS (no ICD-code for a demyelinating disorder) general population reference cohort was randomly selected from the Total Population Register, matched 10:1 on age, sex, country of birth, and year of socioeconomic data. Highest educational level (elementary, high school, or university) was compared using logistic regression. Income, measured as the mean annual earnings from work in Swedish kronor (SEK), was compared using Tobit models, and net annual sickness absence (SA) and disability pension days were compared using zero-inflated negative binomial regression. Income and days on disability benefits were compared within five age periods (19-24; 25-34; 35-44; 45-54; 55-64).

699 PoMS and 6983 matched references were included.  There was no difference in the odds of attending university for PoMS versus the matched references (odds ratio: 0.89; 95%CI: 0.75-1.05). Still, the PoMS cohort had significantly lower annual earnings than the reference cohort, ranging from -19,558 SEK (95%CI: -26,677 to -12,439) in the youngest age period to -230,502 SEK (95%CI: -267,202 to -193,802) in the eldest. PoMS received higher rates of disability benefits, as sickness absence days in the youngest age period (rate ratio (RR): 3.12 (95%CI: 2.19–4.43), and disability pension days in the later age period (RR: 1.31; 95%CI:1.15–1.50).

While having PoMS did not influence educational achievement, it was associated with reduced earnings and increased use of disability benefits throughout the working lifespan. As adults, persons with PoMS never earned as much as their non-MS counterparts.

Authors/Disclosures
Kyla A. McKay, PhD (Karolinska Institutet)
PRESENTER
Dr. McKay has received research support from Canadian Institutes of Health Research. Dr. McKay has received research support from Swedish Research Council for Health, Working Life, and Welfare. Dr. McKay has received research support from ECTRIMS.
No disclosure on file
No disclosure on file
No disclosure on file
Jan A. Hillert, MD (Karolinska Institute, Neurology R54) Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celgene. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sandoz. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. The institution of Dr. Hillert has received research support from Biogen. The institution of Dr. Hillert has received research support from Celgene. The institution of Dr. Hillert has received research support from Merck. The institution of Dr. Hillert has received research support from Novartis. The institution of Dr. Hillert has received research support from Sanofi. The institution of Dr. Hillert has received research support from Roche.